Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barr Tamoxifen Supply Will Hold To Mid-Nov.; Firm Seeks FDA Injunction

Executive Summary

Barr will be unable to supply tamoxifen 10 mg after mid-November in the absence of court action to overrule FDA and allow the immediate launch of the firm's generic

You may also be interested in...



AstraZeneca May Market Unbranded Tamoxifen If Barr Contract Not Resumed

Nolvadex maker AstraZeneca may market its own tamoxifen generic if it cannot reach an agreement with Barr to reinstate the companies' supply and distribution agreement

AstraZeneca May Market Unbranded Tamoxifen If Barr Contract Not Resumed

Nolvadex maker AstraZeneca may market its own tamoxifen generic if it cannot reach an agreement with Barr to reinstate the companies' supply and distribution agreement

Barr’s Tamoxifen Approval Barred Until Resolution Of ANDA “Deficiencies”

Barr must resolve recently identified "deficiencies" in labeling for its tamoxifen ANDA before FDA will grant final approval of the Nolvadex generic, an Oct. 2 agency memo says

Related Content

UsernamePublicRestriction

Register

PS040529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel